Company: LIMN
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001104659-25-111651
Chunk: 2

Company: Liminatus Pharma, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1F
Chunk 2
---
 1,750Additional paid-in capital ​  29,054,337​  9,323,403Accumulated deficit​  (30,702,806)​  (28,665,216)Total stockholders’ deficit​  (1,645,763)​  (19,340,063)Total liabilities and stockholders’ deficit​$ 1,342,409​$ 5,408,859

* Shares, preferred stock amount, common stock amount and additional paid-in capital data are presented on a retroactive basis to reflect the effects of the conversion and recapitalization as a result of the Business Combination consummated on April 30, 2025.​

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

​